STX-241 FIH (F60087CI101)

RMC-LUNG-101A

RMC-LUNG-101

LB100

RMC-6291-101

STX-721-101

StrateGIST 1 (IDRX-42-001)

D6900C00001

CA1201001

M22TGA

CTLR-101

IMC-F106C-101 (PRAME)

TCD17620

MCLA-129-CL01

D9570C00001

GO43860

XL092-001

SGNPDL1V-001

INCB 123667-101

PROACTIVE

1479-0001

CyPep-1

VHIO17002

MCLA-128-CL01

KEYNOTE 158

DESTINY-Lung03

Study of RMC-6291 in Combination With RMC-6236 in Participants With Advanced KRAS G12C Mutant Solid Tumors.



<ul class="wp-block-list">
<li>Code NKI: M23IMC</li>



<li>Code firma: RMC-6291-101</li>



<li>Code clinicaltrials.gov: NCT06128551</li>
</ul>



Principal Investigator



Dr. F. Opdam



Drugs 



<ul class="wp-block-list">
<li>RMC-6291 (orally bioavailable tri-complex inhibitor of the active GTP-bound state of the mutated KRASG12C protein)</li>



<li>RMC-6236 (orally bioavailable RASMULTI(ON) inhibitor, selective for the active GTP-bound state (RAS(ON))</li>
</ul>



About doses:



<ul class="wp-block-list">
<li>Dose escalation: any solid tumors &#8211; open</li>



<li>Dose expansion: CRC, NSCLC &#8211; open</li>
</ul>



<h2 class="wp-block-heading">Summary</h2>



This is an open-label, multicenter, Phase 1b study of RMC-6291 in combination with RMC-6236 in participants with advanced KRAS G12C-mutated solid tumors, to identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose and schedule (RP2DS) and provide a preliminary assessment of the antitumor activity of RMC-6291 in participants with KRASG12C tumors. The study consists of two parts: Part 1 &#8211; Dose-Escalation and Part 2 Dose-Expansion.



Read more on <a href="https://clinicaltrials.gov/study/NCT06128551" data-type="link" data-id="https://clinicaltrials.gov/study/NCT06043817?term=First-In-Human%20Study%20of%20STX-721%20in%20Participants%20With%20Locally%20Advanced%20or%20%20Metastatic%20Non-Small%20Cell%20Lung%20Cancer%20Harboring%20EGFR%20Exon%2020%20Insertion%20%20Mutations&amp;rank=1">clinicaltrials.gov</a>